FX & CFD trading involves significant risk
Merck (MRK) earned $0.87 per share in the fourth quarter, beating analysts' estimate of $0.86. Revenue in the fourth quarter decreased 7.4% year-over-year to $10.48 billion, but exceeding analysts' estimate of $10.47 billion.
The company released its forecasts for 2015. EPS is expected to be $3.32-$3.47 (analysts' estimate: $3.48). Revenue is expected to be $38.3-$39.8 billion (analysts' estimate: $40.95 billion).
Merck (MRK) shares decreased to $60.02 (-1.64%) prior to the opening bell.
All posted material is a marketing communication solely for informational purposes and reliance on this may lead to loss. Past performance is not a reliable indicator of future results. Please read our full disclaimer.